Skip to main content
Published locations for mCRC: Triplet+bevacizumab offers survival advantage even in patients with bone metastasis
Primary tabs
•••
View
Get Stamp Tags
Published Locations
Breadcrumb
Home
mCRC: Triplet+bevacizumab offers survival advantage even in patients with bone metastasis
User login
Username
Password
Reset your password
/content/mcrc-tripletbevacizumab-offers-survival-advantage-even-patients-bone-metastasis
/hematology-oncology/article/259662/gastrointestinal-cancer/mcrc-tripletbevacizumab-offers-survival